Arrowhead Pharmaceuticals Stock Price To Book
| HDP1 Stock | EUR 21.10 0.45 2.18% |
Arrowhead Pharmaceuticals fundamentals help investors to digest information that contributes to Arrowhead Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Arrowhead Stock. The fundamental analysis module provides a way to measure Arrowhead Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Arrowhead Pharmaceuticals stock.
Arrowhead |
Arrowhead Pharmaceuticals Company Price To Book Analysis
Arrowhead Pharmaceuticals' Price to Book (P/B) ratio is used to relate a company book value to its current market price. A high P/B ratio indicates that investors expect executives to generate more returns on their investments from a given set of assets. Book value is the accounting value of assets minus liabilities.
Current Arrowhead Pharmaceuticals Price To Book | 8.32 X |
Most of Arrowhead Pharmaceuticals' fundamental indicators, such as Price To Book, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Arrowhead Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Price to Book ratio is mostly used in financial services industries where assets and liabilities are typically represented by dollars. Although low Price to Book ratio generally implies that the firm is undervalued, it is often a good indicator that the company may be in financial or managerial distress and should be investigated more carefully.
| Competition |
Based on the latest financial disclosure, Arrowhead Pharmaceuticals has a Price To Book of 8.3247 times. This is 67.58% lower than that of the Healthcare sector and 37.83% higher than that of the Biotechnology industry. The price to book for all Germany stocks is 12.46% higher than that of the company.
Arrowhead Price To Book Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Arrowhead Pharmaceuticals' direct or indirect competition against its Price To Book to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Arrowhead Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Arrowhead Pharmaceuticals by comparing valuation metrics of similar companies.Arrowhead Pharmaceuticals is currently under evaluation in price to book category among its peers.
Arrowhead Fundamentals
| Return On Equity | -0.4 | |||
| Return On Asset | -0.13 | |||
| Profit Margin | (0.56) % | |||
| Operating Margin | (0.57) % | |||
| Current Valuation | 2.76 B | |||
| Shares Outstanding | 108.31 M | |||
| Shares Owned By Insiders | 4.93 % | |||
| Shares Owned By Institutions | 69.27 % | |||
| Price To Earning | 263.63 X | |||
| Price To Book | 8.32 X | |||
| Price To Sales | 13.82 X | |||
| Revenue | 243.23 M | |||
| Gross Profit | 243.23 M | |||
| EBITDA | (178.51 M) | |||
| Net Income | (176.06 M) | |||
| Cash And Equivalents | 218.2 M | |||
| Cash Per Share | 2.30 X | |||
| Debt To Equity | 2.40 % | |||
| Current Ratio | 2.31 X | |||
| Book Value Per Share | 3.55 X | |||
| Cash Flow From Operations | (136.13 M) | |||
| Earnings Per Share | (1.29) X | |||
| Target Price | 87.92 | |||
| Number Of Employees | 397 | |||
| Beta | 1.01 | |||
| Market Capitalization | 3.5 B | |||
| Total Asset | 691.94 M | |||
| Net Asset | 691.94 M |
About Arrowhead Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Arrowhead Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Arrowhead Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Arrowhead Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Additional Information and Resources on Investing in Arrowhead Stock
When determining whether Arrowhead Pharmaceuticals is a strong investment it is important to analyze Arrowhead Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Arrowhead Pharmaceuticals' future performance. For an informed investment choice regarding Arrowhead Stock, refer to the following important reports:Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Arrowhead Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. For more detail on how to invest in Arrowhead Stock please use our How to Invest in Arrowhead Pharmaceuticals guide.You can also try the Economic Indicators module to top statistical indicators that provide insights into how an economy is performing.